Live Quote · OTCGBIMHealthcare· Biotechnology

GlobeImmune, Inc.

$0.00 0.00%(+$0.00)
TickerSpark Score
63/100
Mixed
80
Valuation
40
Profitability
80
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBIM research report →

52-Week Range100% of range
Low
$0.00
Current
$0.00
High
$0.00
Company Overviewwww.globeimmune.com

About the company

GlobeImmune, Inc. , a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases.

CEO
Donald Bellgrau
IPO
2014
Employees
2
HQ
Louisville, CO, US

Price Chart

+0.00% · this period
$0.00$0.00$0.00Jul 02Dec 31Jul 02
Valuation
Market Cap
$575
P/E
-0.00
P/S
0.00
P/B
0.00
EV/EBITDA
3.84
Div Yield
0.00%
Profitability
Gross Margin
58.99%
Op Margin
-42.85%
Net Margin
-42.85%
ROE
-64.41%
ROIC
-38.00%
Growth & Income
Revenue
$6.46M · 8.24%
Net Income
$-2,766,905 · 86.27%
EPS
$-0.48 · 93.05%
Op Income
$-2,766,905
FCF YoY
30.74%
Performance & Tape
52W High
$0.00
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
-200.46
Avg Volume
540

Get TickerSpark's AI analysis on GBIM

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Mar 16, 16MITCHELL DANIEL Jsell8,862
Mar 17, 16MITCHELL DANIEL Jsell12,468
Mar 16, 16MITCHELL DANIEL Jsell112
Mar 17, 16MITCHELL DANIEL Jsell158
Mar 11, 16MITCHELL DANIEL Jsell76,662
Mar 15, 16MITCHELL DANIEL Jsell50,831
Mar 11, 16MITCHELL DANIEL Jsell2,131
Mar 15, 16MITCHELL DANIEL Jsell645
Mar 8, 16MITCHELL DANIEL Jsell5,741
Mar 9, 16MITCHELL DANIEL Jsell5,643
Coverage · GBIM

Our GBIM coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on GBIM yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate GBIM report →
Internal Compare

Similar companies

Peers in the same neighborhood.